NovaBay Pharmaceuticals Joins the Russell Microcap Index
NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on
commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that it has
joined the Russell Microcap® Index. Each June, the Russell Microcap Index is realigned and recalibrated to reflect
market changes during the past year with membership primarily determined by objective, market-capitalization rankings and style
attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active
investment strategies. According to FTSE Russell, approximately $8.4 trillion in assets are benchmarked against Russell’s U.S.
indexes.
“Joining the Russell Microcap Index is expected to contribute to increased investor awareness and broaden our investor base as
we continue to build the market for Avenova,” said Mark M. Sieczkarek, NovaBay’s President and CEO. “We attribute our inclusion to
the dramatic strides we’ve made in our turnaround since directing our focus on Avenova commercialization in late 2015. Our outlook
for 2017 is for continued growth with sales to increase 60% year-over-year to $19 million, gross margin on Avenova product sales in
the high 80% range and cash burn of $3 million.”
More information on the Russell Microcap® Index is available on the “Russell Reconstitution” section of the FTSE Russell website.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics ®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of
products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and
CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based upon management's current expectations, assumptions,
estimates, projections and beliefs. These statements include, but are not limited to, statements regarding any potential
benefit or deleterious effect of being included in the Russell Microcap Index, inclusive of any possible effect that would have
generally on the Company’s expected future financial results. Forward-looking statements can be identified with words like (and
variations of): “expect”,” and “outlook.” These statements involve known and unknown risks, uncertainties and other factors that
may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the
forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks
and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company's products, unexpected
adverse side effects or inadequate therapeutic efficacy of our product, the uncertainty of patent protection for the Company's
intellectual property, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that
could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed
in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk
Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or
obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay's progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website
NovaBay Contacts
For NovaBay Avenova purchasing information, please:
Call us toll free: 1-800-890-0329
or email sales@avenova.com
www.Avenova.com
or
From the Company
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact Tom
Investor Contact:
LHA
Jody Cain
310-691-7100
Jcain@lhai.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170626005344/en/